HAVCR2 and cancer: Since Tim-3 is considered to be an ideal target for the next generation of immunotherapy, these findings might suggest that Lnc-Tim3 and its associated signaling pathways may influence the outcome of cancer therapies aimed at modulating the acquired immune system.